Showing results (111-120 of 212) with videos related to
Sort By:
Pageof 22
Investigational New Drugs|September 22, 2010
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumorsMatthew D Galsky, Daniel D Von Hoff, Marcus Neubauer, et al.European Journal of Cancer (Oxford, England : 1990)|December 15, 2015
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)David Goldstein, Daniel D Von Hoff, Malcolm Moore, et al.Targeted Oncology|April 22, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.Pancreas|April 1, 2008
Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancerAmanda F Baker, Mei Y Koh, Ryan R Williams, et al.Journal of Cancer|September 11, 2012
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trialsMitesh J Borad, Kelly K Curtis, Hani M Babiker, et al.The Oncologist|August 18, 2018
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid TumorsGregory L Beatty, Safi Shahda, Thaddeus Beck, et al.Molecular Cancer Therapeutics|July 1, 2010
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancerDavid L Schwartz, James A Bankson, Robert Lemos, et al.British Journal of Cancer|July 22, 2016
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancerN V Rajeshkumar, Shinichi Yabuuchi, Shweta G Pai, et al.Investigational New Drugs|August 31, 2002
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642)Desirée Hao, Jinee D Rizzo, Stephanie Stringer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignanciesBahram Forouzesh, Chris H Takimoto, Andrew Goetz, et al.Pageof 22